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Abstract
While regulatory policy is well defined for orphan drug development in the United States and Europe, rare disease
policy in China is still evolving. Many Chinese patients currently pay out of pocket for international treatments that
are not yet approved in China. The lack of a clear definition and therefore regulatory approval process for rare diseases
has, until now, de-incentivized pharmaceutical companies to pursue rare disease drug development in China. In turn,
many grassroots movements have begun to support rare disease patients and facilitate drug discovery through
research. Recently, the Chinese FDA set new regulatory guidelines for drugs being developed in China, including
an expedited review process for life-saving treatments. In this review, we discuss the effects of these new policy
changes on and suggest potential solutions to innovate orphan drug development in China.
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Background
On April 12, 2016, Zexi Wei died from synovial sar-
coma, a rare form of cancer. Wei was a 21 year-old col-
lege student who had trusted results from the Chinese
Internet search giant Baidu to receive a novel treatment
for his disease. Later he found that the so-called “novel
treatment” was inefficient, and that the hospital was rec-
ommended by Baidu based on paid advertising. After his
death, it was also revealed that the treatment had proved
ineffective in clinical trials in the United States, and that
the Stanford team which appeared in the advertisement
was not involved at all with the Chinese hospital that ad-
ministered his treatment [1]. In the weeks that followed,
Baidu received public outrage and eventually delisted
2,518 medical institutions and removed 126 million ad-
vertisements based on lack of qualifications [2]. While
this case study reveals the terrors of the profit-driven
healthcare advertising model in China, it also points to a
lack of proper rare disease regulatory policy that allowed
false medical claims to be propagated.
The Chinese Food and Drug Administration (CFDA)
regulates the clinical trials and marketing approval of
drugs by evaluating the safety and effectiveness of treat-
ments and ensuring a proper label that highlights the
indications as well as the side of effects of drugs. Rare or
orphan diseases are very conservatively estimated to
affect at least 10 million people in China, and 350 mil-
lion globally, though the estimates in China may be con-
founded by limited reported data [3, 4]. Worldwide sales
for orphan drugs is projected to be $176 billion by the
year 2020, which will comprise almost 20% of total drug
sales [5]. Though the patient need is great and the mar-
ket is huge, the CFDA has yet to design and implement
specialized regulation for orphan drug development.
There has been much activity recently with regard to
the review and approval system for the CFDA. In
November 2015, the definition of a “new drug” was
changed to drugs that had never before been marketed
anywhere in the world, not just in China. Though this is
a forward facing policy for encouraging domestic
innovation, it may still affect the ability of rare disease
patients in China to receive treatment. Currently only
37.8, 24.6 and 52.4% of orphan drugs approved in the
US, EU and Japan, respectively, are available in the
Chinese market [6]. Thus, this new policy by CFDA may
hinder access to life-saving medication for patients with-
out the proper expedited review processes defined for
orphan drugs. This paper provides an overview of global
orphan drug regulation, discusses financial and scientific
challenges in orphan drug development and ends with* Correspondence: alicec33@gmail.com
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the current climate and recommendations for orphan
drug regulation in China.
Understanding US FDA and global regulations for
orphan drug development
First, an understanding of the United States Food and
Drug Administration (US FDA) regulatory process for
rare disease clinical trials is necessary for developing
regulatory policy in China. This section focuses on the
regulatory pathway in the United States because it was
the first country to implement a policy for the develop-
ment of drugs to treat rare diseases with the Orphan
Drug Act of 1983, and has since approved the most
drugs via this pathway. The US FDA defines an orphan
drug as one treating a disease affecting less than 200,000
people in the United States, or one that will not be prof-
itable within 7 years following FDA approval [7]. Thus,
drugs for economically limiting tropical diseases are also
covered. Orphan drugs receive 7 years of market exclu-
sivity beginning after drug approval, which is independ-
ent of patient status. Even after this 7-year monopoly
expires, new competitors cannot enter the market with-
out proving that their drug is superior to the existing
one. Up to one half of research and development costs
can be recouped through tax credits, with up to $30
million per year in R&D grants provided for phase I
through III clinical trials. These incentives also include a
15-year carry forward provision and 3-year carry back
that can be applied once the drug is profitable. In addition,
Federal Food, Drug, and Cosmetic Act (FFDCA) Section
526 allows Prescription Drug User Fee Act (PDUFA) user
fees to be waives, which results in an average savings of $2
million for companies with less than $50 M in revenue.
This provides an incentive for startup companies to de-
velop novel treatments for rare diseases. Section 505A
under the FDA Modernization Act of 1997 also grants an
additional 6 months of patent exclusivity for drugs that
serve the pediatric population, which comprise 50% of the
rare disease population [4, 8].
The Orphan Drug Act has almost unanimously been
considered successful for advancing rare disease treat-
ment in the US. The financial incentives provided to
pharmaceutical companies have increased rare disease
research and drug repositioning opportunities. However,
it has also created an environment where perverse
incentives feedback loops can negatively impact the
healthcare system, and ultimately patients. This has most
notably been seen in recent news with Martin Shrekli’s
strategy of exorbitant price hikes for rare disease drugs
[9]. As CEO of Retrophin, Shrekli increased the price of
rare disease drug Thiola by 2,000% in 2014. As CEO of
Turing Pharmaceuticals, Shrekli executed the same
strategy and increased the price of rare disease drug
Daraprim by over 5,000%. Valeant Pharmaceuticals CEO
Michael Pearson took the same approach, raising drug
prices by up to 1,700% over the course of 6 years in
order to increase shareholder returns [10]. This was jus-
tified to investors as a “capitalistic approach to pricing”
based on “what the market will bear.” As the US health
insurance system moves toward a model of reimburse-
ment as a percentage (instead of a fixed amount) of a
drug’s cost, high prices for rare disease drugs will be
passed on to patients, who are then at the mercy of
pharmaceutical and shareholder profits. Consequently,
some argue that “orphan drug policies have the paradox-
ical effect of creating new orphan patients! [11]”.
Though the US has pioneered structure in rare disease
research and policy, differences in regulatory policy exist
for countries in Europe and Asia (Table 1). One import-
ant discrepancy among regulatory policies is the lack of
a global definition for what constitutes a rare disease.
Therefore, drugs considered for a rare indication in Eur-
ope may not be approved in the United States under an
expedited pathway.
Financial considerations for orphan drug
development
However, most orphan drugs are still unaffordable in
China. With a 5% patient co-pay, only three generic or-
phan drugs were considered affordable by middle-income
Chinese patients [6]. Over 100 commercial health insur-
ance companies exist in China for those who are able to
afford an additional policy to supplement government in-
surance [12]. However, chronic rare diseases are not well
defined for coverage, with approximately 10–15 rare dis-
eases that are covered. A ceiling coverage of only 100,000
yuan is provided for chronic disease in one plan by
Taikang Life Insurance Co., Ltd. For families with children
suffering from a rare disease, a financial contribution can
easily surpass 40%, causing a catastrophic financial bur-
den. In addition, many international drugs not yet
approved by the CFDA are sold in the “gray market” to
patients, who pay cash out of pocket. Many patients can-
not afford these treatments and forego them altogether.
Though CFDA incentivizes companies to develop orphan
drugs, patients must still be able to afford these treat-
ments in order for the market to be sustainable. One pro-
posal by Professor Longjun Gu of Shanghai JiaoTong
University advocates for a rare disease specific fund com-
posed of contributions from the national medical insur-
ance, commercial insurance and government charity [13].
This would help cover costs that are beyond what patients
are able to pay.
Patients have also suggested ways to counter this with
government intervention; FDA could expedite approval
of generics or competing rare disease drugs once the
price of a drug is increased past a certain amount [10].
Japan includes this in its rare disease policy, requiring
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companies receiving profits in excess of 100 M yen for
rare disease drugs to pay back a portion of those profits
to the government (Table 1). The National Institute for
Health and Clinical Excellence (NICE) of England and
Wales defines each quality-adjusted life-year as £20,000–
30,000, with drugs possessing a quality-adjusted life-year
(QALY) of less than £20,000 being more likely to receive
reimbursement [14]. However, metrics for reimburse-
ment are often not disclosed or clearly defined in other
countries. Additionally, it is difficult to use these trad-
itional economic analyses to evaluate orphan drugs,
which are used to treat such a small subset of the popu-
lation. Modified QALY analyses have been proposed,
including a person trade-off (PTO) approach to deter-
mine how many treated individuals would be equiva-
lent to one healthy individual [15].
Current provincial and city initiatives provide medical
insurance and drug reimbursement for rare disease pa-
tients. In Shanghai province, standard medical coverage
of up to 200,000 yuan is provided for 12 specific rare
diseases, though this falls short of an estimated 2 mil-
lion yuan annually needed per patient to cover rare dis-
ease treatment [16, 17]. Since 2012, the city of Qingdao
in the Shandong province has covered treatments fees
of up to 400,000 yuan for all, including orphan, dis-
eases. Though these initiatives help relieve financial bur-
dens of some rare diseases, a national program with
guaranteed coverage for clearly identified rare diseases
will democratize healthcare for all rare disease patients
in China.
For drugs that are currently approved in other countries,
Chinese FDA should lay out specific regulations for ap-
proval or sale. Simplifying registration of foreign-approved
drugs will prevent redundancy in regulation and economic
burden, and increase availability of treatment for patients.
Regardless of approach, political and economic consider-
ations will factor into geographic-specific regulations. As
validation for government subsidies, patient registries with
access to de-identified data have been proposed to ad-
vance public health [18]. For ultra-orphan drugs, a direct
distribution model that trims costs from distributors also
has potential to carry savings directly to patients [19].
Scientific and technical considerations in research
and clinical trials
A major challenge in the approval of rare and ultra-rare
orphan drugs is clinical trial design. Typically, clinical
trial phases 1, 2 and 3 are conducted linearly, with each
phase completed and evaluated in order to inform de-
sign of the next phase (Fig. 1). However, new seamless
designs for clinical trials are being implemented, with
statistical analyses that allow the next phase to begin be-
fore the primary phase has completed [20, 21]. These in-
novative new trial designs require enough statistical
power and can be quite useful for expediting time-to-
market as well as reducing the number of enrolled
patients, saving the sponsor costs. These options are
currently being evaluated for rare disease trials, which
can be even more challenging due to the small patient
population [22]. One recently approved drug for the
treatment of hereditary orotic aciduria, a disease that is
only known to affect 20 people worldwide, completed a
clinical trial with only four patients over 6 weeks [23].
Patient recruitment and retention are the biggest chal-
lenges in clinical trials. The Clinical Trial Act legislation
was implemented in the US to regulate patient compen-
sation during clinical trials. Patients are able to receive
up to $2,000 USD for participating in clinical trials with-
out counting toward taxable income. A standard com-
pensation per visit versus per trial, for traveling and
lodging costs or for home monitoring, is set by the spon-
soring pharmaceutical company instead of the clinical re-
search organization (CRO), and can vary across trials.
Whereas average dropout rates across typical clinical stud-
ies can still exceed 30%, this number may be much lower
for rare disease trials [24]. A new study shows that rare
disease patients are more likely to accept risks in trying
new medications, with drug response ranking as the most
important outcome regardless of treatment modality [25].
In addition, 45% of patient respondents from a survey
taken by the National Organization for Rare Disorders
(NORD) in 2014 expressed that they were willing to use
experimental treatments [19]. These data indicate that
rare disease patients are easier to recruit for and retain
during a clinical trial. This reduces redundancy in patient
Fig. 1 Regulatory schematic of orphan drug development in the United States
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recruitment costs, where many trials must over-recruit to
compensate for drop-out rates.
In a draft guidance to industry on common issues in
orphan drug development by the US FDA, natural his-
tory and disease pathophysiology are cited as important
for having a foundational understanding of the disease
in order to develop appropriate study endpoints [26].
This is especially important for rare disease trials,
which often include pediatric patients with life-
threatening conditions. In the US, the Office of Orphan
Products Development specializes in researching and
implementing orphan drug regulation. A specialized of-
fice for orphan diseases does not yet exist within the
CFDA, but will be necessary as orphan drug and per-
sonalized medicines become a major focus in global
healthcare [27].
Without rigorous clinical trial design and reporting re-
quirements, it will be difficult to evaluate the safety and
effectiveness of drugs. An unregulated landscape can be
seen in traditional Chinese medicine (TCM) clinical tri-
als, where over 60% of studies did not adhere to the
standard Consolidated Standard of Reporting Trials re-
quirements [28]. Training on proper record keeping and
informed consent processes must therefore be rigorous
and strictly implemented in order for Chinese hospitals
and CROs to be competitive for domestic and inter-
national drug development.
A cultural component should also be considered.
Though many traditional Chinese medicines (TCMs) are
merely theatrical placebos, the market is still booming
for herbal cures [29]. The perceived success and desper-
ation of patients for a cure contribute to the placebo re-
sponse not only in China, but also in the United States.
Though the placebo effect was originally higher in China
than in the US, the US has started to see increasing pla-
cebo responses over the past 23 years that now surpass
the drug-placebo effectiveness of other countries [30].
This effect could be exacerbated by drug pricing, with
studies showing that the higher the price of the drug,
the higher the placebo response [31]. It may be fair to
say that this effect could be exaggerated in China, where
paranoia of domestic manufacturing quality lead to in-
creased belief in foreign treatments. The Chinese “anti-
placebo” concept has been documented as far back as
1993, when presumably ill-fated Chinese-Americans died
up to 5 years sooner than Caucasian patients from a var-
iety of causes simply because of their belief in a negative
astrological sign [32]. Alternatively, this phenomenon
may also negatively impact patients who have an in-
creased willingness to participate in a study without the
proper informed consent process, such as was the case
with Mr. Wei and his family. Therefore, educational ma-
terials and the patient consent process should be clearly
outlined for all studies.
Rare disease initiatives in China
In the past, rare diseases did not receive much attention
in China. This could partly be attributed to lack of
awareness, and partly to limitations in diagnostic tech-
nologies. A genetic skeletal disease study from 2012
indicates that genetic testing was performed for only
1.16% of over 16,000 patients [33]. With growing aware-
ness and technological capabilities, China is working
toward a more standardized and comprehensive rare dis-
ease ecosystem. Recent changes proposed by the CFDA
include expedited review for rare disease drugs; however,
this pathway is not well defined. Although there is no of-
ficial definition for a rare disease in China, a bottom-up
analysis of cost-effectiveness proposes that rare diseases
be defined as affecting between 300,000 to 500,000 of
the population [34]. This is based on a $1.2 billion drug
development cost and an optimistic insurance reimburse-
ment ceiling of $50,000 USD per year per patient.
In 2013, the China Rare Diseases Prevention and
Treatment Alliance launched a national pilot to advance
rare disease healthcare, involving over 100 medical cen-
ters over 13 provinces and 0.7 billion people [35]. The
project focuses on 20 rare diseases and hopes to use out-
comes to develop an executable plan for improving rare
disease healthcare by 2018, with the following three aims:
1. Develop and pilot clinical guidelines and standards
for the 20 specified rare diseases. Optimized guidelines
after pilot testing will be implemented in hospitals
nationwide.
2. Establish a patient registry based on retrospective
medical records dating back to 2003 along with
newly diagnosed cases. All data will be de-identified
using Common Data Elements (CDE). A public
patient registry will allow advocacy organizations
to register their own patients.
3. Implement nine single gene and seven next-generation
sequencing analyses for 15 rare diseases to encourage
molecular genetic testing analyses in rare disease
diagnosis, research and care.
In Europe, an additional “ultra-orphan” designation
has been proposed for diseases affecting less than 1 in
50,000 of the population (compared to affecting 1 in
2,000 for rare diseases) [36]. In the United States, ultra-
rare diseases are generally defined as affecting less than
20,000 people [19]. This designation was also officially
proposed via the HR3737 ULTRA (Unlocking Lifesaving
Treatments for Rare-Diseases Act) in December 2011 to
approve certain orphan drugs based on surrogate end-
points [37]. A report on cost-effectiveness of ultra-
orphan drug development in Europe concluded that
traditional criteria for cost-effectiveness cannot be used
for ultra-orphan drugs with such small patient populations
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[36]. Thus, challenges remain for justifying development
costs and subsidies of drugs for ultra-rare diseases. While
it may be premature to designate an “ultra” for currently
undefined “rare” diseases in China, this points to a need
for new ways of evaluating the economic impact of orphan
drug development. As health insurance becomes more of
a focal point for the rapidly aging population, this will also
play into the broader scope of drug reimbursement.
Broader government initiatives for fostering rare dis-
ease research include hosting national scientific forums,
encouraging the formation of research consortiums and
providing an avenue for publication. The Intractable and
Rare Diseases Research journal was established in 2013
with support from the Japan Society for the Promotion
of Science, the Ministry of Education, Culture, Sports,
Science and Technology and the Japanese government
[38]. China could greatly benefit from an English lan-
guage publication platform to advance rare disease re-
search, which will also enhance China’s global scientific
competitiveness.
Collaborating with patient advocacy groups to
build registries and raise awareness
The purpose of drug regulation is to make sure safe and
effective treatments can be developed, and to help pro-
vide a balance in the market while advancing public
health. Therefore, most regulation by FDA or CFDA is
developed by scientific and regulatory experts. Regula-
tory agencies must work closely with patient advocacy
groups to develop policies that can be feasibly imple-
mented. While the government has the power to imple-
ment and enforce rare disease policies, it is ultimately
the patient community that drives change. In the US,
NORD is credited for instituting the Orphan Drug Act
of 1983.
In fact, patient advocacy organizations are not only re-
sponsible for changes in legislation, but are also focused
on research. Ninety percent of rare disease patient orga-
nizations have a goal of advancing research, with 95%
participating in at least one research-related activity in
the past year [39]. Fifteen percent of these organizations
identified research as their primary goal. The Chinese
Organization for Rare Disorders (CORD) was established
in 2013 and is the prominent patient advocacy
organization for rare disease patients. This organization
hosts 23 member organizations and serves as a means of
information dissemination and a voice for patients to
government and industry [40]. Ongoing outreach cam-
paigns have educated over 100 million people in China
about rare diseases. Other public institutions such as the
Shandong Academy of Medical Sciences, Tsinghua Uni-
versity, the Chinese Charity Foundation and the China
Health Education Center have also supported programs
to spread awareness and worked to advance rare disease
research. These organizations will be the biggest advo-
cates and allies in the CFDA’s implementation of orphan
drug regulation.
While rare disease patients are generally informed
about their disease, they may not be aware of clinical
trial opportunities. Additionally, patients may not trust
for-profit companies that reach out to participate in tri-
als. Working with patient advocacy organizations helps
build trust with patients and may increase retention dur-
ing the study. Similar to the generic drug marketing
campaign, the CFDA can work with patient advocacy
groups in China to inform patients about clinical trials.
A national registry with standardized clincal trial demo-
graphic and patient information can also inform clinical
trial site selection. Building a national health registry for
patients with rare diseases in China can be done under
government guidance, with participation between hospi-
tals, research institutions and patient advocacy groups [41].
Conclusions
This paper extensively compared orphan drug develop-
ment and regulatory policy in China and the US. With
many political, economic and cultural differences, China
cannot just base its regulations directly on the US model.
In contrast to the mostly private healthcare system in the
US, where registries can be fragmented across patient ad-
vocacy groups and hospitals, a healthcare system that is
mostly public in China should take advantage of available
data to create aggregated databases for diseases and gen-
omic information. Even without a registry, existing soft-
ware tools such as DISMOD II can be used to aggregate
patient data and analyze rare disease epidemiology across
participating hospitals [42]. We continue to advocate for
the five suggestions proposed by the National People’s
Congress and Chinese People’s Political Consultative Con-
ference of 2009: 1) establishing a definition for rare dis-
eases, 2) developing an orphan drug reimbursement
system, 3) proposing a clear and simple approval pathway
for imported orphan drugs, 4) promoting rare disease re-
search through policy, and 5) developing government-
supported programs for rare disease patients [17]. The
Chinese FDA should also continue working with patient
advocacy groups and research institutions to identify the
most prevalent diseases and patient needs. Clearly defin-
ing regulatory policy for orphan drugs will benefit both
patients and research organizations, and allow China to
serve as a global player in rare diseases.
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